EP63 the TAPAS Study: Thrombectomy Aspiration Post-Market Study in Acute Stroke

Introduction The Q Aspiration catheter design has shown increased aspiration force in bench studies1. The objective of this first clinical study was to assess safety and performance of the Q™ Catheter in a real-world setting. The study was a multi-center, observational, post market study utilizing the Q Catheter as first-line therapy during mechanical thrombectomy in Spain. Methods Patients with AIS treated with Q as first line therapy between March 2019 and January 2020 were identified at four centers in Spain. Inclusion criteria included 18–85 years of age, anterior or posterior LVO, ASPECTs 6–10 and within 8 hours of onset/last known well. Baseline demographics, procedural data, post procedure neuroimaging, and clinical outcomes were reported. A follow up visit was conducted to assess mRS. Results There were 45 patients included. Average age at presentation was 72.4 and 53.3% were male. Thrombolytic therapy was given in 46.7% (21/45) and NIHSS was 14.4 (range 1–26). Final mTICI 2b-3 was achieved in 93% of patients (42/45). First pass success of mTICI 2b-3 with only a Q Catheter was achieved in 49% (21/43), increasing to 56% (24/43) when a stent retriever was used as an anchor. Overall successful revascularization using the Q Catheter was 77% (33/43). ENT was 2% (1), sICH rate was 2% (1), and mortality during the study period was 13% (6). At follow-up, 55.5% of subjects had a mRS of 0–2. Conclusion The Q Catheter showed good deliverability and revascularization rates in this real-world setting with no safety concerns. Reference Long TD, Kallmes DF, Hanel R, Shigematsu T, Halaszyn AM, Wolter J, Berenstein A. Novel aspiration catheter design for acute stroke thrombectomy. J Neurointerv Surg 2019 Feb;11(2):190–195. Disclosure Consultant MIVI Neuroscience, Inc.